# Biotech Growth Trust notes Esperion acquisition agreement

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-notes-esperion-acquisition-agreement/4121252429
- Published: 2026-05-01T15:22:00+01:00
- Author: Amilia Stone

**Biotech Growth Trust plc** (LON:BIOG) has noted the announcement on Friday, 1 
May 2026 that ARCHIMED has entered into an agreement to acquire BIOG portfolio company,
Esperion Therapeutics for approximately $1 billion, or $3.16 per share, in cash,
representing a 58% premium to Esperion’s closing price on Thursday, 30 April 2026.
The offer also includes an additional $100 million in contingent value right payments
which are based on Esperion products achieving certain sales milestones; if met,
the aggregate purchase price would total $1.1 billion.

Esperion is a US-based commercial biopharmaceutical company focused on drugs targeting
cardiovascular disease.   Its lead drugs are oral therapies to lower cholesterol.

The Company’s holding in Esperion represented 2.5% of the Company’s net asset value(
NAV) at the time of the announcement. The transaction will be reflected in the Company’s
NAV as at close of business on 1 May 2026, which will be announced on Tuesday, 5
May 2026.

This follows on from recent acquisitions of portfolio companies Avidity Biosciences,
Cidara Therapeutics, Amicus Therapeutics, Apellis Pharmaceuticals and KalVista Pharmaceuticals.

Share on:
